APOB and hypertriglyceridemia: However, LZP deficiency attenuates apoB-mediated VLDL secretion, leading to lower serum apoB and TG levels in mice; therefore, LZP could be considered a potential therapeutic target for hyperlipemia, especially hypertriglyceridemia.